Welcome to LookChem.com Sign In|Join Free

CAS

  • or

20020-28-4

Post Buying Request

20020-28-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

20020-28-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 20020-28-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,0,0,2 and 0 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 20020-28:
(7*2)+(6*0)+(5*0)+(4*2)+(3*0)+(2*2)+(1*8)=34
34 % 10 = 4
So 20020-28-4 is a valid CAS Registry Number.

20020-28-4Relevant articles and documents

Sustainable organophosphorus-catalysed Staudinger reduction

Lenstra, Danny C.,Lenting, Peter E.,Mecinovi?, Jasmin

supporting information, p. 4418 - 4422 (2018/10/17)

A highly efficient and sustainable catalytic Staudinger reduction for the conversion of organic azides to amines in excellent yields has been developed. The reaction displays excellent functional group tolerance to functionalities that are otherwise prone to reduction, such as sulfones, esters, amides, ketones, nitriles, alkenes, and benzyl ethers. The green nature of the reaction is exemplified by the use of PMHS, CPME, and a lack of column chromatography.

1, 2, 4-TRIAZOLONE DERIVATIVE

-

Paragraph 0411; 0412; 0413, (2013/08/14)

The present invention provides a 1,2,4-triazolone derivative represented by Formula (1A) having an antagonistic activity on the arginine-vasopressin 1b receptor or a pharmaceutically acceptable salt thereof and provides a pharmaceutical composition comprising the compound or the salt as an active ingredient, in particular, a therapeutic or preventive agent exhibiting favorable pharmacokinetics in a disease such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, or alopecia.

Scalable synthesis of the VEGF-R2 kinase inhibitor JNJ-17029259 using ultrasound-mediated addition of MeLi-CeCl3 to a nitrile

Reuman, Michael,Beish, Sandra,Davis, Jeremy,Batchelor, Mark J.,Hutchings, Martin C.,Moffat, David F. C.,Connolly, Peter J.,Russell, Ronald K.

, p. 1121 - 1123 (2008/09/18)

(Chemical Equation Presented) The preparation of the selective VEGF-R2 kinase inhibitor 10 (JNJ-17029259) is described in which the key precursor, 4-(5-isoxazolyl)benzonitrile, undergoes clean transformation to the corresponding cumylamine derivative with

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 20020-28-4